FDA:
FDA approved Veklury (remdesivir) for adults and pediatric patients 12 years of age and older for the treatment of COVID-19 requiring hospitalization
www.fda.gov
“The FDA is committed to expediting the development and availability of COVID-19 treatments during this unprecedented public health emergency,” said FDA Commissioner Stephen M. Hahn, M.D. “Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed and represents an important scientific milestone in the COVID-19 pandemic. As part of the FDA’s Coronavirus Treatment Acceleration Program, the agency will to continue to help move new medical products to patients as soon as possible, while at the same time determining whether they are effective and if their benefits outweigh their risks.”
NIH:
Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo.
www.nih.gov
NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19
Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21.
---
In a review of several trials, the World Health Organization found that Gilead’s drug did not improve survival rates for patients nor did it help them recover.
www.nytimes.com
W.H.O. Rejects Antiviral Drug Remdesivir as a Covid Treatment
In a review of several trials, the World Health Organization found that Gilead’s drug did not improve survival rates for patients nor did it help them recover.
Remdesivir has been authorized for emergency use since the spring in the United States, and in October, Gilead reported that it had generated $873 million in revenue thus far this year.
The drug’s widely adopted use for Covid symptoms had baffled some experts well before the F.D.A. approval.
“This is an entirely appropriate decision by the W.H.O.,” Dr. Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, wrote in an email. “Remdesivir costs thousands of dollars, the largest randomized trial examining its use in Covid suggests it may have no benefit of any kind, and the one positive study dates back to a time before we were using dexamethasone for severe disease,” he added, referring to a steroid now commonly used in hospitals.
----
So let's recap.
The FDA and NIH finds expensive drug (Remdesivir) safe and successful in Covid treatment and quickly approved it. [Gilead reported that it had generated $873 million in revenue thus far this year - 2020]
"Total first quarter 2021 revenue of
$6.4 billion increased 16% compared to the same period in 2020, primarily due to Veklury® (remdesivir) sales, Cell Therapy growth with Yescarta® (axicabtagene ciloleucel) and the U.S. launch of Tecartus"
The WHO finds it did not improve in Covid treatment.
Better deplatform/ban these spreaders of fakenews with that silly abbreviation called the "WHO", right?
@Dave
"Big pharma" aka Gilead in this case - totally legit and the profits could certainly have
nothing to do with anything getting stamped with approval by the FDA and NIH, surely?